VX-745 is primarily investigated for its potential therapeutic applications, particularly in the treatment of inflammatory diseases. It functions as a selective inhibitor of p38 mitogen-activated protein kinase (MAPK), a key enzyme involved in the regulation of inflammatory responses. By inhibiting this pathway, VX-745 has shown promise in reducing the production of pro-inflammatory cytokines, which are often elevated in conditions such as rheumatoid arthritis and other autoimmune disorders. Its application in preclinical studies has demonstrated efficacy in mitigating inflammation and associated tissue damage, making it a candidate for further development in anti-inflammatory therapies. However, its clinical use has been limited due to safety concerns, particularly regarding central nervous system toxicity. Ongoing research aims to refine its pharmacological profile to enhance its therapeutic potential while minimizing adverse effects.